Tender detail
Non-exclusive discount agreement for sevelamer hydrochloride medicines
Summary
DAK-Gesundheit is seeking non-exclusive pharmaceutical discount agreements for medicines containing the active substance sevelamer hydrochloride (ATC V03AE02). The agreements are scheduled to run from 1 January 2027 to 31 December 2028, with an option to extend for one further 12-month period, and will end earlier if an exclusive agreement takes effect.
More tender information after sign-in
The public view shows key tender details. Sign in to open official links, documents and AI tender support.